114 related articles for article (PubMed ID: 22806958)
21. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.
Antoch G; Kanja J; Bauer S; Kuehl H; Renzing-Koehler K; Schuette J; Bockisch A; Debatin JF; Freudenberg LS
J Nucl Med; 2004 Mar; 45(3):357-65. PubMed ID: 15001674
[TBL] [Abstract][Full Text] [Related]
22. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography.
Mori T; Nomori H; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
J Thorac Oncol; 2008 Apr; 3(4):358-64. PubMed ID: 18379353
[TBL] [Abstract][Full Text] [Related]
23. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
24. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
[TBL] [Abstract][Full Text] [Related]
25. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
26. Does positron emission tomography data acquisition impact simultaneous diffusion-weighted imaging in a whole-body PET/MRI system?
Buchbender C; Hartung-Knemeyer V; Heusch P; Heusner TA; Beiderwellen K; Wittsack HJ; Kühl H; Forsting M; Bockisch A; Antoch G; Lanzman RS
Eur J Radiol; 2013 Feb; 82(2):380-4. PubMed ID: 23238361
[TBL] [Abstract][Full Text] [Related]
27. Tumor detection by diffusion-weighted MRI and ADC-mapping--initial clinical experiences in comparison to PET-CT.
Lichy MP; Aschoff P; Plathow C; Stemmer A; Horger W; Mueller-Horvat C; Steidle G; Horger M; Schafer J; Eschmann SM; Kiefer B; Claussen CD; Pfannenberg C; Schlemmer HP
Invest Radiol; 2007 Sep; 42(9):605-13. PubMed ID: 17700275
[TBL] [Abstract][Full Text] [Related]
28. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
Shankar S; vanSonnenberg E; Desai J; Dipiro PJ; Van Den Abbeele A; Demetri GD
Radiology; 2005 Jun; 235(3):892-8. PubMed ID: 15833985
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of positron emission and computed tomography scan in early evaluation of treatment response in gastrointestinal stromal tumor.
Nozaki Y; Yanase M; Masaki N
Clin Gastroenterol Hepatol; 2010 Mar; 8(3):A22. PubMed ID: 19362609
[No Abstract] [Full Text] [Related]
30. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
31. Correlation between tissue metabolism and cellularity assessed by standardized uptake value and apparent diffusion coefficient in peritoneal metastasis.
Yu X; Lee EY; Lai V; Chan Q
J Magn Reson Imaging; 2014 Jul; 40(1):99-105. PubMed ID: 24170710
[TBL] [Abstract][Full Text] [Related]
32. Current directions in systemic therapy for gastrointestinal stromal tumors.
Chugh R
Curr Probl Cancer; 2011; 35(5):255-70. PubMed ID: 22118565
[No Abstract] [Full Text] [Related]
33. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
[TBL] [Abstract][Full Text] [Related]
34. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
[TBL] [Abstract][Full Text] [Related]
35. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
Holdsworth CH; Badawi RD; Manola JB; Kijewski MF; Israel DA; Demetri GD; Van den Abbeele AD
AJR Am J Roentgenol; 2007 Dec; 189(6):W324-30. PubMed ID: 18029844
[TBL] [Abstract][Full Text] [Related]
36. Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma?
Punwani S; Prakash V; Bainbridge A; Taylor SA; Bandula S; Olsen OE; Hain SF; Shankar A; Daw S; Humphries P
Cancer Biomark; 2010; 7(4):249-59. PubMed ID: 21576817
[TBL] [Abstract][Full Text] [Related]
37. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer.
Ho KC; Lin G; Wang JJ; Lai CH; Chang CJ; Yen TC
Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):200-8. PubMed ID: 18779960
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of diffusion-weighted magnetic resonance imaging compared with fluorodeoxyglucose positron emission tomography/computed tomography for pancreatic malignancy: a meta-analysis using a hierarchical regression model.
Wu LM; Hu JN; Hua J; Liu MJ; Chen J; Xu JR
J Gastroenterol Hepatol; 2012 Jun; 27(6):1027-35. PubMed ID: 22414092
[TBL] [Abstract][Full Text] [Related]
39. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
[TBL] [Abstract][Full Text] [Related]
40. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
